Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avaxia Biologics has received Phase I Small Business Innovation Research (SBIR) grant for the development of new antibody therapeutic to treat celiac disease from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH).
Subscribe to our email newsletter
This Phase I award offers Avaxia a sum of around $145,000 in research and development funds.
Avaxia founder and CEO Barbara Fox said they are delighted to have been awarded this grant from the NIH in recognition of the potential of the novel approach to the treatment of celiac disease.
"This NIH support provides the funding we need to advance the development of our anti-gluten antibody into pre-clinical models of celiac disease," Fox said.